FY2025 EPS Estimates for VERA Decreased by Cantor Fitzgerald

Vera Therapeutics, Inc. (NASDAQ:VERA) – Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Vera Therapeutics in a report issued on Monday, May 12th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings per share of ($2.79) for the year, down from their previous forecast of ($2.74). Cantor Fitzgerald has a “Overweight” rating and a $100.00 price objective on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same period last year, the firm posted ($0.56) earnings per share.

A number of other equities research analysts also recently issued reports on VERA. JPMorgan Chase & Co. reduced their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. Wolfe Research started coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock. Wedbush lowered their price target on Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, May 7th. HC Wainwright started coverage on Vera Therapeutics in a research note on Monday, May 5th. They issued a “buy” rating and a $75.00 price objective for the company. Finally, Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Vera Therapeutics currently has an average rating of “Buy” and an average price target of $63.33.

Vera Therapeutics Trading Up 0.7%

NASDAQ VERA opened at $21.33 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The stock has a market capitalization of $1.36 billion, a P/E ratio of -8.17 and a beta of 1.28. The firm’s 50-day moving average is $23.63 and its two-hundred day moving average is $34.16. Vera Therapeutics has a 12 month low of $18.53 and a 12 month high of $51.61.

Institutional Investors Weigh In On Vera Therapeutics

Several large investors have recently bought and sold shares of VERA. Avoro Capital Advisors LLC boosted its stake in shares of Vera Therapeutics by 30.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock valued at $237,247,000 after buying an additional 1,300,410 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Vera Therapeutics by 8.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company’s stock valued at $114,212,000 after acquiring an additional 377,783 shares in the last quarter. FMR LLC lifted its stake in Vera Therapeutics by 9.6% in the fourth quarter. FMR LLC now owns 3,053,126 shares of the company’s stock worth $129,117,000 after acquiring an additional 267,842 shares during the last quarter. Vanguard Group Inc. grew its holdings in Vera Therapeutics by 14.3% during the 4th quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock worth $124,737,000 after acquiring an additional 369,387 shares in the last quarter. Finally, Vestal Point Capital LP increased its position in shares of Vera Therapeutics by 132.6% in the 1st quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock valued at $60,050,000 after purchasing an additional 1,425,000 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.